#pharmaceutical

バイオファーマ企業は国際ライセンス契約を再構成しており、最恵国待遇価格設定規則への暴露を削減している。この規則は米国の医薬品価格を他国で支払われた最低価格と連動させている。

Ugur Sahin and Ozlem Tureci will exit BioNTech by year-end to start a company focused on next-generation mRNA innovations.

Pharmaceutical giant GSK has agreed to buy 35Pharma, a biotech focused on pulmonary hypertension, for $950 million. The deal expands GSK's respiratory and cardiovascular portfolio with a pipeline targeting a disease that currently has limited treatment options.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.